Patent · US Active

Treatment of ACVR1-mediated diseases

US10245268B2 · kind B2 · utility

1Cited by
1References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 8, 2017
Grant dateApr 2, 2019
Priority date—
Expiry dateAug 8, 2037

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are methods, compositions, and kits for treating ACVR-1-mediated diseases using N-(cyanomethyl)-4-[2-4-morpholinoanilino)pyrimidin-4-yl]benzamide.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.